---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000792"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T13:20:04.451876+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025

## Summary
- Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.
- Announced $3.0M private placement with Chairman Gregg Williams entity at $1.03/share (2.9M shares).
- LIBERATE-1 Phase 1 study on track; all NPM-115 (exenatide) implant insertions successful; top-line results mid-2025.
- Promising preclinical data for NPM-139 semaglutide implant for chronic weight management in obese/overweight.
- Plans to spin off Cortigent brain implant division as an independent publicly traded company.

## SEC filing metadata
- accession: 0001753926-25-000792
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000792/0001753926-25-000792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000792/vani-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000792
- JSON: https://secwatch.observer/filing/0001753926-25-000792.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.